Synco specialises in manufacturing live microbial biopharmaceuticals and the takeover is a vital move for Wacker to maintain its position in the highly competitive biopharmaceuticals market.
Munich/Germany – Wacker Chemie has acquired a Dutch site for manufacturing biopharmaceuticals, live microbial products and vaccines, plus the associated business, from Synco Bio Luxembourg. The Munich-based chemical company announced the acquisition today. For Wacker, maintaining Synco’s existing customer relationships is a top priority. Moreover, Wacker is keeping on Synco’s employees. Both parties have agreed not to disclose the purchase price.
Founded in 2000, Synco Bio Partners has some 110 employees and operates two fermentation lines with current capacities of 1,500 and 270 liters. These lines manufacture microbial-derived biopharmaceuticals, not only for clinical testing, but also for the commercial market. There is a further line of single-use fermenters, which provides additional and flexible production capabilities.
Synco’s service offering is rounded out with a ‘fill and finish’ facility, which enables the complete manufacture of pharmaceuticals from the active agent to the filled product. The facilities meet ‘Good Manufacturing Practice’ (GMP) quality standards, and they have already been inspected by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) and approved for the manufacture of specific pharmaceutical proteins.
Synco’s expertise in manufacturing live microbial biopharmaceuticals is a valuable complement to Wacker’s know-how as a full-service supplier. Live microbial products represent a promising new class of actives, offering innovative therapies for serious illnesses and new vaccines against cholera, for example.